Triple O Research Inst
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Osiyemi, Olayemi
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting
3
171
Europe, Canada, US, RoW
DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys
ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP
HIV Infections
10/25
10/26
NCT06741397: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Not yet recruiting
2
200
US
CAB LA, New formulation of CAB LA
ViiV Healthcare
HIV Infections
08/26
12/28
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26

Download Options